FOXM1-specific TCR-engineered T cells target non-small cell lung cancer - PubMed
7 hours ago
- #non-small cell lung cancer
- #FOXM1
- #TCR-engineered T cells
- FOXM1 is highly expressed in various cancers and drives cancer progression.
- Immunogenic FOXM1 epitopes were identified on HLA-A*02:01, HLA-A*24:02, and HLA-A*23:01.
- TCR-engineered T cells targeting FOXM1 showed sensitivity and specificity in tests.
- Adoptive transfer of FOXM1-specific TCR-T cells reduced tumor growth and prolonged survival in mice.
- The study confirms FOXM1's immunogenicity and the feasibility of TCR-engineered T cell therapy.